NCT00344825已完成不适用
Observational Study for Evaluation of Quality of Life in Patients Under Treatment for B-Chronic Lymphocytic Leukemia.
Genzyme, a Sanofi Company0 个研究点目标入组 300 人开始时间: 2004年1月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 300
研究概览
简要总结
300 patients, starting a new pharmacological treatment for B-CLL, were enrolled by 36 Italian Centres for assessing the Quality of Life (QoL). A descriptive analysis of QoL and the correlation of the age, sex, stage of disease, Time from first B-CLL diagnosis, Number of previous B-CLL treatments, reason of starting of the new B-CLL treatment: therapeutic Regimen, type of Centre, B-CLL treatment lasting, response to B-CLL treatment.
详细描述
The study has previously been posted by Schering AG, Germany. Schering AG, Germany has been renamed to Bayer Schering Pharma AG, Germany.
Bayer Schering Pharma AG, Germany is the sponsor of the trial.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Aged >/=18 years
- •Patients of either sex with B-CLL, who are starting a new pharmacological treatment for B-Chronic Lymphocytic Leukemia (1st, 2nd, 3rd, 4th)
- •Foreseen duration of CLL therapy </= 6 months
- •B-Chronic Lymphocytic Leukemia progressive stage A, stage B or C (according to Binet system), or II-IV (according to Rai system)
- •WHO Performance Status </= 2
- •Life expectancy </= 6 months
- •Signed Informed consent for personal data's treatment and availability to fill in the QoL questionnaire
排除标准
- •Patients with any other tumour disease
- •Chronic Lymphocytic Leukemia therapy in the last 30 days before V0
- •More than 3 previous CLL treatments (the therapy is defined by the drug and/or the treatment period)
- •Previous stem cells transplantation
- •Concurrent or in the last 30 days participation to any other clinical trial
- •Any medical or psychological conditions that might compromise the capacity to sign the consent for personal data's treatment or to fill in the QoL questionnaire
研究组 & 干预措施
Group 1
干预措施: Alemtuzumab (MabCampath, BAY86-5045) and Fludarabine Phosphate (Fludara, BAY86-4864) (Drug)
研究者
相似试验
进行中（未招募）
不适用
Observational Study Relapsed or Refractory Chronic Lymphocytic Leukemia Venetoclax-based Regimens Outside Clinical Trials in ItalyRelapse LeukemiaRefractory LeukemiaChronic Lymphocytic LeukemiaNCT04282811Gruppo Italiano Malattie EMatologiche dell'Adulto321
已完成
不适用
Efficacy and Safety of Bendamustine Plus Rituximab in Chronic Lympocytic LeukemiaChronic Lymphocytic LeukemiaNCT02491398Gruppo Italiano Malattie EMatologiche dell'Adulto494
Unknown
不适用
Italian Multicenter Retrospective Observational Study on Transformed LymphomasNon-Hodgkin Lymphoma Transformed RecurrentNCT02927756A.O.U. Città della Salute e della Scienza180
Unknown
不适用
Interim FDG PET/CT in Diffuse Large B Cell Lymphoma (DLBCL) PatientsLymphoma, Large B-Cell, DiffuseNCT01357733The Catholic University of Korea53
已完成
1 期
Treatment of B-CLL With Human IL-2 and CD40 Ligand and Plasmid Gene Modified Autologous Tumor CellsLeukemiaLeukemia, B-Cell, ChronicNCT00078520Baylor College of Medicine9